Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2025)
Candel Therapeutics recorded quarterly Return on Capital Employed of 48.07% in Q4 2025, down 5.07% quarter-over-quarter from 45.75% in Q3 2025, and up 7709.0% year-over-year from 0.62% in Q4 2024.
Candel Therapeutics' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 48.07% for Q4 2025.
- In Q4 2025, Return on Capital Employed rose 7709.0% year-over-year to 48.07%; the TTM figure through Dec 2025 stood at 48.07% (up 7709.0% YoY), while the FY2025 annual figure was 45.09%, up 4632.0% from the prior year.
- Return on Capital Employed came in at 48.07% for Q4 2025 at Candel Therapeutics, down from 45.75% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 29.5% in Q4 2021 to a low of 407.05% in Q3 2024.
- A 5-year average of 92.3% and a median of 46.96% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 32495 bps in 2024 and jumped 36130 bps in 2025, its largest moves.
- Candel Therapeutics' Return on Capital Employed stood at 29.5% in 2021, then plunged by 55 bps to 45.85% in 2022, then slumped by 166 bps to 122.08% in 2023, then decreased by 3 bps to 125.16% in 2024, then soared by 62 bps to 48.07% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 48.07%, 45.75%, and 41.99% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | -48.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -48.07% |
| Sep 30, 2025 | -45.75% |
| Jun 30, 2025 | -41.99% |
| Mar 31, 2025 | -41.32% |
| Dec 31, 2024 | -125.16% |
| Sep 30, 2024 | -407.05% |
| Jun 30, 2024 | -240.00% |
| Mar 31, 2024 | -161.70% |
| Dec 31, 2023 | -122.08% |
| Sep 30, 2023 | -82.11% |
| Jun 30, 2023 | -66.04% |
| Mar 31, 2023 | -52.61% |
| Dec 31, 2022 | -45.85% |
| Sep 30, 2022 | -41.27% |
| Jun 30, 2022 | -36.60% |
| Mar 31, 2022 | -33.43% |
| Dec 31, 2021 | -29.50% |
| Sep 30, 2021 | -40.90% |